Leticia Bornstein-Quevedo

Dr. Leticia Bornstein-Quevedo


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LBLeticia Bornstein-Quevedo
Leticia Bornstein-Quevedo
JAJazmín de Anda-González
Jazmín de Anda-González
CLCesar Octavio Lara-Torres
Cesar Octavio Lara-Torres
JFJuan Pablo Flores-Gutiérrez
Juan Pablo Flores-Gutiérrez
RDRita Dorantes-Heredia
Rita Dorantes-Heredia
CAClaudia Arce-Salinas
Claudia Arce-Salinas
The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population of patients with HER2-low-expressing BC. While current guidelines recommend a dichotomous classification of HER2 as either positive or negative, the emergence of the HER2-low concept calls for standardization of HER2 testing in breast cancer, using currently available assays to better discriminate HER2 levels. This review covers the evolution and latest updates of the ASCO/CAP guidelines relevant to this important biomarker in breast cancer, including still-evolving concepts such as HER2 low, HER2 heterogeneity, and HER2 evolution. Our group presents the latest Mexican recommendations for HER2 status evaluation in breast cancer, considering the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, accurate HER2 status assessment remains one of the most important biomarkers in breast cancer, and the commitment of Mexican pathologists to theragnostic biomarker quality is crucial for providing the most efficient care in oncology.

5 April 2023 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
CBClaudia Bautista-Wong
Claudia Bautista-Wong
ZMZaira Mojica-González
Zaira Mojica-González
KHKatia Hop-Garcia
Katia Hop-Garcia
LBLeticia Bornstein-Quevedo
Leticia Bornstein-Quevedo
Pan-TRK antibodies have been used to detect gene fusions in diverse types of tumors. Several tyrosine receptor kinases (TRK) inhibitors have recently been developed and have shown good response rates in neoplasms with NTRK; therefore, identifying these fusions is an essential tool in assessing treatment options for certain oncological diseases. Various algorithms have been designed to diagnose and detect NTRK fusions to optimize time and resources. This study explores the use of immunohistochemistry (IHC) as a screening method for NTRK fusions by comparing next-generation sequencing (NGS) and IHC to evaluate the pan-TRK antibody’s performance as a marker for NTRK rearrangements. The present work studied 164 formalin-fixed paraffin-embedded blocks of different solid tumors. Two pathologists confirmed the diagnosis and selected the correct area to assess with IHC and NGS. Specific cDNAs were generated for the genes involved. NTRK fusions were identified in 4 patients positive for the pan-TRK antibody through NGS. The identified fusions were NTRK1-TMP3, NTRK3-EML4, and NTRK3-ETV6. That shows sensitivity and specificity of 100% and 98%, respectively. NTRK fusions were identified in 4 patients positive for the pan-TRK antibody through NGS. IHC tests (with the pan-TRK antibody) are a sensitive and specific method for identifying the presence of NTRK1-3 fusions.

19 March 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
EMElisa Garcia Martinez
Elisa Garcia Martinez
LLLeonardo A Lino-Silva
Leonardo A Lino-Silva
ARAdriana Romo-Pérez
Adriana Romo-Pérez
LBLeticia Bornstein-Quevedo
Leticia Bornstein-Quevedo
ABALMA DELIA CHAVEZ BLANCO
ALMA DELIA CHAVEZ BLANCO
ADAlfonso Dueñas-González
Alfonso Dueñas-González
Background/Objectives: To evaluate the immunohistochemical expression of hexokinase-2 (HK2), glutaminase-1 (GLS1), and fatty acid synthase (FASN) and its prognostic significance in diffuse gastric adenocarcinoma. Materials and Methods: Formalin-fixed paraffin-embedded tissue samples from 92 patients with diffuse gastric adenocarcinoma were analyzed. Immunohistochemistry (IHC) was performed to assess the expression of HK2, GLS1 and FASN. Expression levels were evaluated semi-quantitatively based on staining intensity and the percentage of positive cells. Associations between enzyme expression and clinicopathological features were assessed using the Chi-square test. Kaplan–Meier survival analysis was employed to evaluate progression-free survival (PFS) and overall survival (OS) and the log-rank test and Cox proportional hazards models were used for statistical analysis. Results: HK2 and FASN were overexpressed in 20.7% and 22.8% of patients, respectively, and were significantly associated with advanced tumor stage. In contrast, GLS1 expression, found in 30.4% of patients, did not independently correlate with clinicopathological characteristics. Furthermore, HK2 expression and co-expression of HK2/FASN (10.9%) and HK2/GLS1/FASN (8.7%) were associated with progressive disease. In the univariate analysis, stage, HK2 overexpression, and co-expression of HK2/FASN and HK2/GLS1/FASN were associated with shorter survival. However, only stage retained prognostic value in the multivariate analysis. Conclusions: Co-expression of these key metabolic enzymes remains a promising candidate as prognostic markers and therapeutic targets. Concurrent targeting of these metabolic pathways may offer novel therapeutic opportunities for patients with advanced-stage gastric cancer.

19 September 2023 in Mexican Journal of Oncology
Verified
Journal Article
Open access
PDF file
LBLeticia Bornstein-Quevedo
Leticia Bornstein-Quevedo
CBClaudia Bautista-Wong
Claudia Bautista-Wong
ZMZaira Mojica-González
Zaira Mojica-González
MGMario Gámez-Rosales
Mario Gámez-Rosales
KHKatia Hop-García
Katia Hop-García
Objective: To assess the prevalence of tropomyosin receptor kinase (TRK) fusions in cancer patients in Mexico. Material and methods: In a basket study, the presence of neurotrophic tyrosine receptor kinase (NTRK) fusion genes was determined by immunohistochemistry and next-generation sequencing in patients with various neoplasms. Results: A total of 677 patients were evaluated. The most frequent cancer types were central nervous system cancer (CNS) (15.1%), lung cancer (14.8%), sarcoma (14.6%), and digestive tube cancer (12.1%). NTRK fusion genes were detected in 4% of the total samples, and in 12.12% of pediatric samples. The most frequent fusions were BTCR-NTRK2 (22.2%), ETV6-NTRK (18.5%), and BCAN-NTRK-1, LMNA-NTRK1, TPM3-NTRK1, and 1AP-NTRK2 (7.4% each). CNS cancer presented the highest frequency (77.8%) of NTRK fusion genes. Conclusions: About 4% of the patients evaluated presented NTRK fusion genes, and most of them had CNS cancer. These patients could benefit from TRK inhibitors therapy.

8 March 2023 in Mexican Journal of Oncology
Verified
Journal Article
Closed access
PDF file
LBLeticia Bornstein-Quevedo
Leticia Bornstein-Quevedo
CBClaudia Bautista-Wong
Claudia Bautista-Wong
ZMZaira Mojica-González
Zaira Mojica-González
MGMario Gámez-Rosales
Mario Gámez-Rosales
KHKatia Hop-García
Katia Hop-García